| Symbol | STRO |
|---|---|
| Name | SUTRO BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 111 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650-881-6500 |
| Fax | — |
| — | |
| Website | https://www.sutrobio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001382101 |
| Description | Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Additional info from NASDAQ: |
Wigginton Jon Marc 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read morePetree Daniel H 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read morePANEK JAMES P 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreLobacki Joseph M 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreJagpal Sukhi 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreHunter Heidi 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreDybbs Michael 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000006
Read moreMATSUI CONNIE 🟢 acquired 10.0K shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) at $26.09 Transaction Date: Jun 05, 2026 | Filing ID: 000002
Read moreChow Gregory K. 🟡 adjusted position in 0 shares (1 derivative) of SUTRO BIOPHARMA, INC. (STRO) Transaction Date: Jun 02, 2026 | Filing ID: 000005
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase1 | Head and Neck Squamous Cell Carcinoma HNSCC | Recruiting | 2025-11-07 | 2028-04-01 | ClinicalTrials.gov |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age Wit… | Phase1 | Acute Myeloid Leukemia (AML) | Terminated | 2024-12-04 | 2025-06-01 | ClinicalTrials.gov |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastat… | Phase2 | Lung Cancer | Withdrawn | 2024-08-21 | 2025-05-01 | ClinicalTrials.gov |
| NCT06238687 | A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other … | Phase1 | Neoplasm Malignant | Completed | 2023-11-08 | 2025-12-30 | ClinicalTrials.gov |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevi… | Phase2 | Ovarian Cancer | Terminated | 2023-07-12 | 2025-08-26 | ClinicalTrials.gov |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in … | Phase1 | Ovarian Cancer | Terminated | 2022-03-22 | 2025-06-01 | ClinicalTrials.gov |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugat… | Phase1 | Ovarian Cancer | Completed | 2019-02-01 | 2024-06-04 | ClinicalTrials.gov |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advan… | Phase1 | B-cell Lymphoma | Completed | 2018-02-22 | 2024-03-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Luveltamab tazevibulin | Other | Phase PHASE2 | Lung Cancer | WITHDRAWN | NCT06555263 |
| STRO-001 | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT03424603 |
| STRO-002 | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03748186 |
| Luveltamab tazevibulin | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT06679582 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT05200364 |
| STRO-002 | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT05200364 |
| Topotecan | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Gemcitabine | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Pegfilgrastim | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Luveltamab tazevibulin | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma HNSCC | RECRUITING | NCT07227168 |
| STRO-004 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma HNSCC | RECRUITING | NCT07227168 |
| STRO-002 | Other | Phase PHASE1 | Neoplasm Malignant | COMPLETED | NCT06238687 |
| Pembrolizumab | DRUG | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma HNSCC | RECRUITING | NCT07227168 |
| STRO-004 | DRUG | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma HNSCC | RECRUITING | NCT07227168 |
| Topotecan | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Pegylated liposomal doxorubicin | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Paclitaxel | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Gemcitabine | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Pegfilgrastim | DRUG | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT05870748 |
| Luveltamab tazevibulin | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT06679582 |
| Bevacizumab | DRUG | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT05200364 |
| STRO-002 | BIOLOGICAL | Phase PHASE1 | Neoplasm Malignant | COMPLETED | NCT06238687 |
| STRO-001 | DRUG | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT03424603 |